Literature DB >> 17802642

De novo production of antigen-specific suppressor cells in vivo.

Karsten Kretschmer1, Tracy S P Heng, Harald von Boehmer.   

Abstract

Foxp3-expressing regulatory T cells (Treg) play an essential role in maintaining tolerance to self antigens and are generated under physiological conditions when developing T cells encounter antigens expressed by thymic epithelial cells. We have addressed the possibility that Treg can be exploited to prevent or even suppress ongoing immune responses to foreign antigens. To this end, one must develop methods that permit the de novo generation of Treg specific for foreign antigens in peripheral lymphoid tissue. This report describes the methodology of generating Treg by delivering minute doses of peptide contained in fusion Abs directed against the DEC-205 endocytic receptor on steady-state dendritic cells. The process, from cloning and production of fusion Abs to antigen-specific Treg induction in vivo, takes approximately 2 months. The results show that delivery of T-cell receptor agonist ligands under subimmunogenic conditions represents a suitable approach for converting naive T cells into Treg.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17802642     DOI: 10.1038/nprot.2006.105

Source DB:  PubMed          Journal:  Nat Protoc        ISSN: 1750-2799            Impact factor:   13.491


  28 in total

Review 1.  Regulatory T-cell therapy for inflammatory bowel disease: more questions than answers.

Authors:  Megan E Himmel; Yu Yao; Paul C Orban; Theodore S Steiner; Megan K Levings
Journal:  Immunology       Date:  2012-06       Impact factor: 7.397

2.  Promoting tolerance to proteolipid protein-induced experimental autoimmune encephalomyelitis through targeting dendritic cells.

Authors:  Joel N H Stern; Derin B Keskin; Zenichiro Kato; Hanspeter Waldner; Sonja Schallenberg; Ana Anderson; Harald von Boehmer; Karsten Kretschmer; Jack L Strominger
Journal:  Proc Natl Acad Sci U S A       Date:  2010-09-20       Impact factor: 11.205

3.  Genomic definition of multiple ex vivo regulatory T cell subphenotypes.

Authors:  Markus Feuerer; Jonathan A Hill; Karsten Kretschmer; Harald von Boehmer; Diane Mathis; Christophe Benoist
Journal:  Proc Natl Acad Sci U S A       Date:  2010-03-15       Impact factor: 11.205

Review 4.  Mechanisms of self-nonself discrimination and possible clinical relevance.

Authors:  Carolin Daniel; Jens Nolting; Harald von Boehmer
Journal:  Immunotherapy       Date:  2009-07       Impact factor: 4.196

Review 5.  Targeted antigen delivery to DEC-205⁺ dendritic cells for tolerogenic vaccination.

Authors:  Cathleen Petzold; Sonja Schallenberg; Joel N H Stern; Karsten Kretschmer
Journal:  Rev Diabet Stud       Date:  2012-12-28

Review 6.  Stem cells--meet immunity.

Authors:  Tracy S P Heng; Jarrod A Dudakov; Danika M P Khong; Ann P Chidgey; Richard L Boyd
Journal:  J Mol Med (Berl)       Date:  2009-10-16       Impact factor: 4.599

Review 7.  Harnessing memory adaptive regulatory T cells to control autoimmunity in type 1 diabetes.

Authors:  Cheng-Rui Li; Bas J G Baaten; Linda M Bradley
Journal:  J Mol Cell Biol       Date:  2011-11-24       Impact factor: 6.216

8.  Designing the optimal vaccine: the importance of cytokines and dendritic cells.

Authors:  Penelope A Morel; Michael S Turner
Journal:  Open Vaccine J       Date:  2010

9.  Dendritic cells require a systemic type I interferon response to mature and induce CD4+ Th1 immunity with poly IC as adjuvant.

Authors:  M Paula Longhi; Christine Trumpfheller; Juliana Idoyaga; Marina Caskey; Ines Matos; Courtney Kluger; Andres M Salazar; Marco Colonna; Ralph M Steinman
Journal:  J Exp Med       Date:  2009-06-29       Impact factor: 14.307

10.  Early increases in superantigen-specific Foxp3+ regulatory T cells during mouse mammary tumor virus infection.

Authors:  Gabriel Cabrera; Dalia Burzyn; Juliana Mundiñano; M Cecilia Courreges; Gabriela Camicia; Daniela Lorenzo; Héctor Costa; Susan R Ross; Irene Nepomnaschy; Isabel Piazzon
Journal:  J Virol       Date:  2008-05-21       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.